ATA-3219 is under clinical development by Atara Biotherapeutics and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData, Phase I drugs for Mantle Cell Lymphoma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ATA-3219’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ATA-3219 overview
ATA-3219 is under development for the treatment of relapsed/refractory B-Cell non-Hodgkin lymphoma, diffuse large b-cell lymphoma, follicular lymphoma, mantle cell lymphoma, autoimmune diseases including systemic lupus erythematosus, multiple sclerosis and lupus nephritis. The drug candidate acts by targeting CD19. It comprise of genetically engineered allogeneic chimeric antigen receptor-modified T cells and is developed based on the Epstein Barr virus (EBV) T-cell platform. It is developed based on 1XX co-stimulation technology. It is administered through intravenous route.
Atara Biotherapeutics overview
Atara Biotherapeutics (Atara) is a biotechnology company that specializes in T-cell immunotherapy, focusing on its innovative allogeneic Epstein-Barr virus (EBV) T-cell platform for developing therapies for patients with cancer and autoimmune disease. Its product pipeline includes tab-cel (Ebvallo) for the treatment of EBV+ post-transplant lymphoproliferative disease (EBV+ PTLD) and ATA3219, an allogeneic CAR T therapy targeting CD19. The company’s preclinical programs include ATA3431 for dual CD19/CD20 targeting in B-cell malignancies, ATA188 for EBV in multiple sclerosis, and an innovative EBV vaccine research. Atara is headquartered in Thousand Oaks, California, the US.
For a complete picture of ATA-3219’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
